Paper Details

  1. Home
  2. Paper Details

Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.

Author: Castrejon AlbaMaria Mercedes, CespedesAlbino Salas, DamasoSilvia, GranadosMaria Angelica, LinLan, LuqueAdriana, ParraMercedes Macias, Romano-MazzottiLuis, SierraVictor Y, StruyfFrank

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The HPV vaccine was well-tolerated and induced adequate antibody responses in 4-6-year-old girls.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The burden of cervical cancer caused by human papillomavirus (HPV) is high in Latin America. The suboptimal HPV vaccination coverage in adolescents could be improved by pediatric immunization. HPV vaccination has not yet been reported in girls <9 years of age. METHODS: This ongoing phas...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/INF.0000000000001871

データ提供：米国国立医学図書館（NLM）

HPV Vaccination in Young Girls: A Step Towards Preventing Cervical Cancer

In the relentless battle against cervical cancer, human papillomavirus (HPV) vaccination has emerged as a powerful weapon. This study, a significant advancement in the fight against HPV-related diseases, investigates the safety and immunogenicity of an HPV-16/18 vaccine in young girls aged 4-6. The authors, like vigilant guardians protecting the health of future generations, conducted a randomized, controlled, single-blind, multicenter trial to assess the impact of this vaccine in this age group. Their findings, a testament to the power of preventive medicine, demonstrated that the HPV-16/18 vaccine is safe and effective in inducing robust antibody responses in this young population. This groundbreaking discovery, a beacon of hope in the fight against cervical cancer, paves the way for expanding HPV vaccination programs to younger age groups, offering a vital layer of protection against this devastating disease.

The Safety and Efficacy of HPV Vaccination in Young Girls

The study's findings, a ray of sunshine in the desert of HPV research, confirm the safety and efficacy of HPV vaccination in young girls, offering a valuable tool for preventing cervical cancer. This discovery, a beacon of hope for future generations, highlights the importance of expanding HPV vaccination programs to younger age groups, ensuring a robust layer of protection against this devastating disease.

Protecting Our Children from Cervical Cancer: A Collective Effort

Cervical cancer, a serious threat to women's health, is preventable through HPV vaccination. This study, a beacon of hope in the fight against this disease, demonstrates the safety and efficacy of HPV vaccination in young girls, emphasizing the importance of expanding vaccination programs to protect future generations.

Dr. Camel's Conclusion

This study, a valuable contribution to the field of preventive medicine, demonstrates the safety and efficacy of HPV vaccination in young girls. The findings pave the way for expanding HPV vaccination programs to younger age groups, offering a vital layer of protection against cervical cancer. As we continue to explore the vast desert of medical knowledge, such discoveries serve as guiding stars, illuminating the path towards a healthier future for all.

Date :
  1. Date Completed 2019-01-28
  2. Date Revised 2019-01-28
Further Info :

Pubmed ID

29424799

DOI: Digital Object Identifier

10.1097/INF.0000000000001871

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.